Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03820817 · ClinicalTrials.gov registry record · Phase 1
Rifaximin in Patients With Monoclonal Gammopathy
A Phase 1 study of Waldenstrom Macroglobulinemia and Light Chain Deposition Disease, sponsored by Emory University.
- Active
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT03820817 is a Phase 1 study of Waldenstrom Macroglobulinemia and Light Chain Deposition Disease that is active but no longer recruiting, run by Emory University. The registered enrollment target is 50 participants, below the 472-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03820817, a Phase 1 study of Waldenstrom Macroglobulinemia and Light Chain Deposition Disease, is active but no longer recruiting, sponsored by Emory University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies how well rifaximin works in treating patients with monoclonal gammopathy. Antibiotics, such as rifaximin, may help to kill bacteria in the intestines and reduce the abnormal protein or cells in patients with monoclonal gammopathy.
Conditions Studied
Interventions
- DRUG Rifaximin
Study Locations (1)
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2025-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03820817
The ClinicalTrials.gov registry entry for NCT03820817 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 472-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (89% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Waldenstrom Macroglobulinemia appearing as the primary indexed condition, and to 1 intervention - of which Rifaximin is the first listed.
NCT03820817 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT03820817 about?
NCT03820817 is a clinical study titled "Rifaximin in Patients With Monoclonal Gammopathy". This trial studies how well rifaximin works in treating patients with monoclonal gammopathy. Antibiotics, such as rifaximin, may help to kill bacteria in the intestines and reduce the abnormal protein or cells in patients with monoclonal gammopathy.
What is the current status of trial NCT03820817?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2019-05-15. Estimated completion is 2025-11-30.
What conditions does trial NCT03820817 study?
This clinical trial studies the following conditions: Waldenstrom Macroglobulinemia, Light Chain Deposition Disease, Monoclonal Gammopathy, IgA Monoclonal Gammopathy, IgG Monoclonal Gammopathy.
What interventions are being tested in trial NCT03820817?
The interventions under investigation include: Rifaximin (DRUG).
Who is sponsoring clinical trial NCT03820817?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03820817 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Waldenstrom Macroglobulinemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
Study of SGR-1505 in Mature B-Cell Neoplasms
RECRUITING · Phase 1
-
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
RECRUITING · Phase 1
-
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.